title: Resveratrol as an adjunct therapy in cyclophosphamide-treated MCF-7 cells and breast tumor explants.
abstract: Cyclophosphamide (CPA) has efficacy as a breast cancer therapy. However, toxicity to CPA limits its clinical applications. Hence there is a need to develop compounds that may be combined with it to improve the efficacy and overcome toxicity. We showed previously that Resveratrol (RES), a chemopreventive agent, increased the growth inhibitory effect of CPA-treated MCF-7 cells. Here we have explored the molecular basis of 5 mM CPA and 50 μM RES as a combination on cell-cycle progression, apoptosis and oxidative stress in MCF-7 breast cancer cells. Efficacy of the combination was also evaluated in a serum-free tumor explant culture model. The combination elicited enhanced anti-proliferative action coupled with differential expression of cell-cycle, apoptosis and stress factors. Furthermore, co-treatment superiority in histologically validated ER positive breast cancer explants suggests that this combination may be a worthy future clinical anti-neoplastic regimen.
authors.affiliation: Tissue and Cell Culture Unit, Central Drug Research Institute, CSIR, Lucknow, India. neetuaashi@yahoo.com
authors.forename: Neetu
authors.initials: N
authors.lastname: Singh
authors.forename: Manisha
authors.initials: M
authors.lastname: Nigam
authors.forename: Vishal
authors.initials: V
authors.lastname: Ranjan
authors.forename: Deeba
authors.initials: D
authors.lastname: Zaidi
authors.forename: Vivek Kumar
authors.initials: VK
authors.lastname: Garg
authors.forename: Sharad
authors.initials: S
authors.lastname: Sharma
authors.forename: Rashmi
authors.initials: R
authors.lastname: Chaturvedi
authors.forename: Rishi
authors.initials: R
authors.lastname: Shankar
authors.forename: Sadan
authors.initials: S
authors.lastname: Kumar
authors.forename: Ramesh
authors.initials: R
authors.lastname: Sharma
authors.forename: Kalyan
authors.initials: K
authors.lastname: Mitra
authors.forename: Anil K
authors.initials: AK
authors.lastname: Balapure
authors.forename: Srikanta K
authors.initials: SK
authors.lastname: Rath
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000648:ultrastructure; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D047468:Immunoprecipitation; D046529:Microscopy, Electron, Transmission; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage*; D014407:Tumor Cells, Cultured
chemical_list: D013267:Stilbenes; D003520:Cyclophosphamide; D000077185:Resveratrol